

Section 1.	ldentifying Inform	ation	17 No. 18 4	A Widow No. 19 Oct			
Given Name (First Peer Brehm			e (Last Name	e)		3. Date 02-February-2	2014
4. Are you the corres	ponding author?	√Yes	No				
5. Manuscript Title Første orale Hepati	tis C behandling mar	kedsført					
6. Manuscript Identif	ying Number (if you kno	ow it)					
			÷				
Section 2.	he Work Under Co	nsideratio	n for Pul	dication			
statistical analysis, etc. Are there any releva If yes, please fill out	nt conflicts of interes	t? Yes	s	data monitoring	g board, s	nent, commercial, private study design, manuscript partition of the study design of th	preparation,
Name of Institution	/Company	Giaiit.	ersonal N ees?	on-Financial Support?	Other?	Comments	
Abbvie	Manual concession and the second constraints of the second constraints				1	Principal investigator	the state of the state of the state of
Brsitol-Myers Squibb					1	Principal investigator	
anssen-Cilag					1	Principal investigator	
Merck Sharp & Dohme	q.				1	Principal investigator	
Section 3. Rol	evant financial ac						
	and the second s						
or compensation) with	ox. You should repor	a in the inst t relationsh	ructions. L	Ise one line for	each en	ial relationships (regard tity; add as many lines a <b>36 months prior to p</b> o	action and b.



Section 4. Intellegence December 2
Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Christensen reports other from Abbvie, other from Brsitol-Myers Squibb, other from Janssen-Cilag, other from Merck Sharp & Dohme, during the conduct of the study;
N. Control of the Con

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



1. Given Name (First Name) Nina	2. Surname (Last Name) Weis		3. Date 02-February-2014
4. Are you the corresponding author?	Yes ✓ No	Corresponding Aut Christensen PB	hor's Name
5. Manuscript Title Første orale Hepatitis C behandling m	arkedsført		
6. Manuscript Identifying Number (if you l	know it)		
Section 2. The Work Under 0	Consideration for Public	cation	
are there any relevant conflicts of inte	rest?		
Section 3. Relevant financial Place a check in the appropriate boxes of compensation) with entities as described.	l activities outside the s in the table to indicate who ribed in the instructions. Us	ether you have finan se one line for each e	ntity; add as many lines as you need
Relevant financia  Place a check in the appropriate boxes of compensation) with entities as describicking the "Add +" box. You should re	l activities outside the s in the table to indicate who ribed in the instructions. Us eport relationships that wer	ether you have finan se one line for each e	ntity; add as many lines as you need
Relevant financia  Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should reached the sound of the sound the s	I activities outside the sering the table to indicate who ribed in the instructions. Use port relationships that were rest?	ether you have finan se one line for each e	ntity; add as many lines as you need
Relevant financial Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should reare there any relevant conflicts of interfyes, please fill out the appropriate info	in the table to indicate who ribed in the instructions. Use port relationships that werest? Yes No formation below.  Grant? Personal Non	ether you have finan se one line for each e	ntity; add as many lines as you need e 36 months prior to publication.
Relevant financial Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should retare there any relevant conflicts of interfyes, please fill out the appropriate information of the same of Entity	in the table to indicate who ribed in the instructions. Use port relationships that were rest? Yes No formation below.  Grant? Personal Non	ether you have finan se one line for each e re present during th	ntity; add as many lines as you need e 36 months prior to publication.
Relevant financial Place a check in the appropriate boxes of compensation) with entities as describicking the "Add +" box. You should refer there any relevant conflicts of interfyes, please fill out the appropriate information ame of Entity	in the table to indicate who ribed in the instructions. Use port relationships that were rest? Yes No formation below.  Grant? Personal Non	ether you have finance one line for each ere present during the control of the co	ntity; add as many lines as you need e 36 months prior to publication.  Comments  Principal Investigator, Speaker,
Place a check in the appropriate boxes of compensation) with entities as descricking the "Add +" box. You should refer there any relevant conflicts of interfyes, please fill out the appropriate information of Entity  Stol-Myers Squibb	in the table to indicate who ribed in the instructions. Use port relationships that were rest? Yes No formation below.  Grant? Personal Non	ether you have finance one line for each ere present during the one-Financial upport?	ntity; add as many lines as you need e 36 months prior to publication.  Comments  Principal Investigator, Speaker, Advisory Board
Section 3. Relevant financial Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should refer there any relevant conflicts of interest fixes, please fill out the appropriate information of the stol-Myers Squibb ead rck Sharp Dohme xo Smtih Kline	in the table to indicate who ribed in the instructions. Use port relationships that were rest? Yes No formation below.  Grant? Personal Non	ether you have finance one line for each ere present during the one-financial upport?	ntity; add as many lines as you need e 36 months prior to publication.  Comments  Principal Investigator, Speaker, Advisory Board  Speaker, Advisory Borad

Weis



Section 4. Intellectual Property Patents & Copyrights				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo				
Section 5. Relationships not covered above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?				
Yes, the following relationships/conditions/circumstances are present (explain below):				
No other relationships/conditions/circumstances that present a potential conflict of interest				
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.				
Section 6. Disclarate Statement				
Disclosure Statement				
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.				
Dr. Weis reports other from Bristol-Myers Squibb, other from Gilead, other from Merck Sharp Dohme, other from Glaxo Smtih Kline, other from Janssen Cilag, outside the submitted work; .				

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



Section 1.	Identifying Inform	ation				
1. Given Name (Fir Alex Lund	st Name)	2. Surnar Laursen	ne (Last Name)			3. Date 05-February-2014
4. Are you the corr	esponding author?	Yes	<b>✓</b> No	Corresponding Author's Name		
5. Manuscript Title Første orale hepatitis C behandling markedsført						
6. Manuscript Iden	itifying Number (if you kn	ow it)				
Section 2.	The Work Under Co	onsiderat	ion for Public	ation		
any aspect of the su statistical analysis, e	ubmitted work (including	but not lim				commercial, private foundation, etc.) for design, manuscript preparation,
Section 3.	Relevant financial	activities	outside the s	ubmitted v	work.	
of compensation) clicking the "Add Are there any rele	with entities as descri	bed in the ort relationst?	instructions. Us nships that wer 'es	e one line fo	r each entity	elationships (regardless of amount ; add as many lines as you need by months prior to publication.
Name of Entity		Grant?		-Financial	Other? Co	omments
Merck Sharp & Dome			<b>✓</b>		<b>✓</b> prin	cipel investigator
Bristol Myers Sqibb			$\checkmark$			
Gilead			$\checkmark$			
	Intellectual Propert					
Do you have any p	patents, whether plann	ed, pendir	ng or issued, bro	oadly relevar	nt to the worl	k? ☐ Yes ✓ No

Laursen



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	rts personal fees and other from Merck Sharp & Dome, personal fees from Bristol Myers Sqibb, personal fees side the submitted work; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.